Neumora Therapeutics, Inc.
NMRADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How NMRA's past catalysts played out
NMRA-335140
Major Depressive Disorder
NMRA-335140 80 mg
Major Depressive Episode Associated With Bipolar II Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NMRA-335140 | Phase 3 | Major Depressive Disorder | - | - |
NMRA-335140 80 mg | Phase 2 | Major Depressive Episode Associated With Bipolar II Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Neumora Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Neumora Therapeutics, Inc.'s (NMRA) pipeline across Phase 3, Phase 2. Its lead program is NMRA-335140 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Neumora Therapeutics, Inc.'s next FDA catalyst?→
Neumora Therapeutics, Inc.'s (NMRA) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NMRA biotech catalysts?→
Add NMRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Neumora Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.